Infantile Spasms (IS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Infantile spasms (IS), or West syndrome, one of the most recognized types of epileptic encephalopathy, constitutes a distinct and often catastrophic form of epilepsy of early infancy. The disorder presents with a unique seizure type, infantile spasms, characterized by flexor, extensor, and mixed flexor–extensor spasms; distinct electroencephalography (EEG) pattern of hypsarrhythmia; and psychomotor delay/arrest. IS can be classified by two etiologies: symptomatic and cryptogenic. Patients with symptomatic IS have a clearly defined underlying cause and/or significant developmental delay prior to the onset of spasms. In cryptogenic IS, no underlying cause is identified, and normal development is present prior to the onset of spasms. Causes of IS may be prenatal, perinatal, or postnatal. Approximately 50% of cases have a prenatal cause, which includes central nervous system malformations, intrauterine insults, neurocutaneous syndromes such as tuberous sclerosis complex (TSC), metabolic disorders, and genetic syndromes such as Down’s syndrome.
·
The incidence of IS ranges from 3.7 to 4.2 per
10,000 live births. Most cases present at the peak age of onset between 3 and 7
months, with 90% of patients presenting in the first year; onset after 18
months is rare, although onset up to 4 years of age.
Thelansis’s “Infantile Spasms (IS)
Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2021 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Infantile Spasms (IS) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Infantile Spasms (IS) across the 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Infantile Spasms (IS) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment